Profil
Jean-Pierre Julien has founded ImStar Therapeutics, Inc. in 2012 and currently holds the position of Director & Chief Scientific Officer.
Postes actifs de Jean-Pierre Julien
| Sociétés | Poste | Début |
|---|---|---|
ImStar Therapeutics, Inc.
 ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | Fondateur | 01/01/2012 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
ImStar Therapeutics, Inc.
ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | Health Technology |
